{"Clinical Trial ID": "NCT00291135", "Intervention": ["INTERVENTION 1:", "- Letrozole", "Letrozole, 2.5 mg daily for six months"], "Eligibility": ["Incorporation criteria:", "Testimony of hyperplasia with/without atypia during random aspiration of the fine peri-areolar needle from the breast", "- Hormonal replacement therapy", "After menopause", "Increased risk of developing breast cancer based on personal or family history", "Never taken aromatase inhibitors or oestrogen receptor selective modulators in the last six months", "Women at high risk of breast cancer", "\u2022 Over 18 years of age", "- Exclusion criteria:", "Anticoagulants", "- Marked breast sensitivity", "\u2022 Pregnant women or within 12 months of breastfeeding/birth"], "Results": ["Performance measures:", "Change in the proliferation of breast epithelial cells obtained by aspiration of random periareolar needles.", "Assessment of immunocytochemical proliferation using Ki-67. Expressed as a percentage of positive cell coloration for Ki-67.", "Target date: Baseline, 6 months", "Results 1:", "Title of the arm/group: Letrozole", "Description of the arm/group: Letrozole, 2.5 mg per day for six months", "Total number of participants analysed: 42", "Median (full range)", "Unit of measure: % change in positive cells for Ki-67 -2.3 (-21.0 to 7.8)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/42 (0.00 per cent)"]}